Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Edit functionality is currently unavailable.

Joshua J Gagne, Sc.D., Pharm.D.

Co-Author

This page shows the publications co-authored by Joshua Gagne and Sebastian Schneeweiss.
Connection Strength

16.100
  1. Gagne JJ, Najafzadeh M, Choudhry NK, Bykov K, Kahler KH, Martin D, Rogers JR, Schneeweiss S. Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation Study. Value Health. 2015 Dec; 18(8):1057-62.
    View in: PubMed
    Score: 0.709
  2. Gagne JJ, Bykov K, Najafzadeh M, Choudhry NK, Martin DP, Kahler KH, Rogers JR, Schneeweiss S. Prospective Benefit-Risk Monitoring of New Drugs for Rapid Assessment of Net Favorability in Electronic Health Care Data. Value Health. 2015 Dec; 18(8):1063-9.
    View in: PubMed
    Score: 0.707
  3. Gagne JJ, Wang SV, Rassen JA, Schneeweiss S. A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. Pharmacoepidemiol Drug Saf. 2014 Jun; 23(6):619-27.
    View in: PubMed
    Score: 0.639
  4. Gagne JJ, Rassen JA, Choudhry NK, Bohn RL, Patrick AR, Sridhar G, Daniel GW, Liu J, Schneeweiss S. Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel. Drug Saf. 2014 Mar; 37(3):151-61.
    View in: PubMed
    Score: 0.631
  5. Gagne JJ, Bykov K, Willke RJ, Kahler KH, Subedi P, Schneeweiss S. Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research. Value Health. 2013 Sep-Oct; 16(6):1054-62.
    View in: PubMed
    Score: 0.608
  6. Gagne JJ, Schneeweiss S. Comment on 'empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership'. Stat Med. 2013 Mar 15; 32(6):1073-4.
    View in: PubMed
    Score: 0.591
  7. Gagne JJ, Glynn RJ, Rassen JA, Walker AM, Daniel GW, Sridhar G, Schneeweiss S. Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. Clin Pharmacol Ther. 2012 Jul; 92(1):80-6.
    View in: PubMed
    Score: 0.558
  8. Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology. 2012 Mar; 23(2):238-46.
    View in: PubMed
    Score: 0.550
  9. Gagne JJ, Avorn J, Shrank WH, Schneeweiss S. Comment: generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies. Ann Pharmacother. 2012 Feb; 46(2):303-4; author reply 304.
    View in: PubMed
    Score: 0.546
  10. Gagne JJ, Walker AM, Glynn RJ, Rassen JA, Schneeweiss S. An event-based approach for comparing the performance of methods for prospective medical product monitoring. Pharmacoepidemiol Drug Saf. 2012 Jun; 21(6):631-9.
    View in: PubMed
    Score: 0.544
  11. Gagne JJ, Fireman B, Ryan PB, Maclure M, Gerhard T, Toh S, Rassen JA, Nelson JC, Schneeweiss S. Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf. 2012 Jan; 21 Suppl 1:32-40.
    View in: PubMed
    Score: 0.543
  12. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011 Jul; 64(7):749-59.
    View in: PubMed
    Score: 0.507
  13. Gagne JJ, Avorn J, Shrank WH, Schneeweiss S. Refilling and switching of antiepileptic drugs and seizure-related events. Clin Pharmacol Ther. 2010 Sep; 88(3):347-53.
    View in: PubMed
    Score: 0.491
  14. Gagne JJ, Patrick AR, Wang PS, Schneeweiss S. Health advisories and patterns of patient monitoring among new users of antidepressant medications. J Clin Psychopharmacol. 2009 Dec; 29(6):590-4.
    View in: PubMed
    Score: 0.470
  15. Gagne JJ, Griesdale DE, Schneeweiss S. Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta-analysis of epidemiologic studies. Pharmacoepidemiol Drug Saf. 2009 Apr; 18(4):259-68.
    View in: PubMed
    Score: 0.449
  16. Fralick M, Colacci M, Schneeweiss S, Huybrechts KF, Lin KJ, Gagne JJ. Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study. Ann Intern Med. 2020 04 07; 172(7):463-473.
    View in: PubMed
    Score: 0.240
  17. Connolly JG, Glynn RJ, Schneeweiss S, Gagne JJ. Improving measurement of binary covariates in claims data: A simulation study. Pharmacoepidemiol Drug Saf. 2020 09; 29(9):1093-1100.
    View in: PubMed
    Score: 0.238
  18. Connolly JG, Schneeweiss S, Glynn RJ, Gagne JJ. Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study. Drug Saf. 2019 11; 42(11):1355-1363.
    View in: PubMed
    Score: 0.234
  19. Bohn J, Schneeweiss S, Glynn RJ, Toh S, Wyss R, Desai R, Gagne JJ. Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches. EGEMS (Wash DC). 2019 Jul 15; 7(1):27.
    View in: PubMed
    Score: 0.229
  20. Najafzadeh M, Schneeweiss S, Choudhry NK, Avorn J, Gagne JJ. General Population vs. Patient Preferences in Anticoagulant Therapy: A Discrete Choice Experiment. Patient. 2019 04; 12(2):235-246.
    View in: PubMed
    Score: 0.224
  21. Bykov K, Schneeweiss S, Glynn RJ, Mittleman MA, Gagne JJ. A Case-Crossover-Based Screening Approach to Identifying Clinically Relevant Drug-Drug Interactions in Electronic Healthcare Data. Clin Pharmacol Ther. 2019 07; 106(1):238-244.
    View in: PubMed
    Score: 0.224
  22. Bykov K, Mittleman MA, Glynn RJ, Schneeweiss S, Gagne JJ. The Case-Crossover Design for Drug-Drug Interactions: Considerations for Implementation. Epidemiology. 2019 03; 30(2):204-211.
    View in: PubMed
    Score: 0.223
  23. Connolly JG, Schneeweiss S, Glynn RJ, Gagne JJ. Quantifying bias reduction with fixed-duration versus all-available covariate assessment periods. Pharmacoepidemiol Drug Saf. 2019 05; 28(5):665-670.
    View in: PubMed
    Score: 0.223
  24. Kumamaru H, Lee MP, Choudhry NK, Dong YH, Krumme AA, Khan N, Brill G, Kohsaka S, Miyata H, Schneeweiss S, Gagne JJ. Using Previous Medication Adherence to Predict Future Adherence. J Manag Care Spec Pharm. 2018 Nov; 24(11):1146-1155.
    View in: PubMed
    Score: 0.218
  25. Wang SV, Jin Y, Fireman B, Gruber S, He M, Wyss R, Shin H, Ma Y, Keeton S, Karami S, Major JM, Schneeweiss S, Gagne JJ. Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses. Am J Epidemiol. 2018 08 01; 187(8):1799-1807.
    View in: PubMed
    Score: 0.214
  26. Krumme AA, Glynn RJ, Schneeweiss S, Choudhry NK, Tong AY, Gagne JJ. Defining Exposure in Observational Studies Comparing Outcomes of Treatment Discontinuation. Circ Cardiovasc Qual Outcomes. 2018 07; 11(7):e004684.
    View in: PubMed
    Score: 0.213
  27. Najafzadeh M, Schneeweiss S, Choudhry NK, Wang SV, Gagne JJ. Simulation for Predicting Effectiveness and Safety of New Cardiovascular Drugs in Routine Care Populations. Clin Pharmacol Ther. 2018 11; 104(5):1008-1015.
    View in: PubMed
    Score: 0.209
  28. Wang SV, Huybrechts KF, Fischer MA, Franklin JM, Glynn RJ, Schneeweiss S, Gagne JJ. Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. Pharmacoepidemiol Drug Saf. 2018 04; 27(4):383-390.
    View in: PubMed
    Score: 0.207
  29. Krumme AA, Pawar A, Schneeweiss S, Glynn RJ, Choudhry NK, Kulldorff M, Ortiz AS, Avorn J, Gagne JJ. Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study. J Comp Eff Res. 2018 01; 7(1):57-66.
    View in: PubMed
    Score: 0.205
  30. Najafzadeh M, Gagne JJ, Schneeweiss S. Synergies From Integrating Randomized Controlled Trials and Real-World Data Analyses. Clin Pharmacol Ther. 2017 Dec; 102(6):914-916.
    View in: PubMed
    Score: 0.203
  31. Wang SV, He M, Jin Y, Wyss R, Shin H, Ma Y, Keeton S, Fireman B, Karami S, Major JM, Schneeweiss S, Gagne JJ. A review of the performance of different methods for propensity score matched subgroup analyses and a summary of their application in peer-reviewed research studies. Pharmacoepidemiol Drug Saf. 2017 Dec; 26(12):1507-1512.
    View in: PubMed
    Score: 0.203
  32. Bykov K, Schneeweiss S, Glynn RJ, Mittleman MA, Bates DW, Gagne JJ. Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis. Drug Saf. 2017 10; 40(10):923-932.
    View in: PubMed
    Score: 0.202
  33. Dong YH, Bykov K, Choudhry NK, Donneyong MM, Huybrechts KF, Levin R, Schneeweiss S, Gagne JJ. Clinical Outcomes of Concomitant Use of Warfarin and Selective Serotonin Reuptake Inhibitors: A Multidatabase Observational Cohort Study. J Clin Psychopharmacol. 2017 Apr; 37(2):200-209.
    View in: PubMed
    Score: 0.195
  34. Bykov K, Schneeweiss S, Donneyong MM, Dong YH, Choudhry NK, Gagne JJ. Impact of an Interaction Between Clopidogrel and Selective Serotonin Reuptake Inhibitors. Am J Cardiol. 2017 02 15; 119(4):651-657.
    View in: PubMed
    Score: 0.190
  35. Hallas J, Pottegård A, Wang S, Schneeweiss S, Gagne JJ. Persistent User Bias in Case-Crossover Studies in Pharmacoepidemiology. Am J Epidemiol. 2016 11 15; 184(10):761-769.
    View in: PubMed
    Score: 0.190
  36. Gagne JJ, Han X, Hennessy S, Leonard CE, Chrischilles EA, Carnahan RM, Wang SV, Fuller C, Iyer A, Katcoff H, Woodworth TS, Archdeacon P, Meyer TE, Schneeweiss S, Toh S. Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug-Adverse Event Association. Clin Pharmacol Ther. 2016 Nov; 100(5):558-564.
    View in: PubMed
    Score: 0.187
  37. Wang SV, Franklin JM, Glynn RJ, Schneeweiss S, Eddings W, Gagne JJ. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. BMJ. 2016 May 24; 353:i2607.
    View in: PubMed
    Score: 0.184
  38. Kumamaru H, Schneeweiss S, Glynn RJ, Setoguchi S, Gagne JJ. Dimension reduction and shrinkage methods for high dimensional disease risk scores in historical data. Emerg Themes Epidemiol. 2016; 13:5.
    View in: PubMed
    Score: 0.183
  39. Kumamaru H, Gagne JJ, Glynn RJ, Setoguchi S, Schneeweiss S. Comparison of high-dimensional confounder summary scores in comparative studies of newly marketed medications. J Clin Epidemiol. 2016 08; 76:200-8.
    View in: PubMed
    Score: 0.181
  40. Wangge G, Schneeweiss S, Glynn RJ, Gagne JJ. Developing alerting thresholds for prospective drug safety monitoring. Pharmacoepidemiol Drug Saf. 2016 07; 25(7):755-62.
    View in: PubMed
    Score: 0.178
  41. Gagne JJ, Polinski JM, Rassen JA, Fischer MA, Seeger JD, Franklin JM, Liu J, Schneeweiss S, Choudhry NK. Selective Serotonin Reuptake Inhibitor Use and Perioperative Bleeding and Mortality in Patients Undergoing Coronary Artery Bypass Grafting: A Cohort Study. Drug Saf. 2015 Nov; 38(11):1075-82.
    View in: PubMed
    Score: 0.177
  42. Najafzadeh M, Schneeweiss S, Choudhry N, Bykov K, Kahler KH, Martin DP, Gagne JJ. A unified framework for classification of methods for benefit-risk assessment. Value Health. 2015 Mar; 18(2):250-9.
    View in: PubMed
    Score: 0.168
  43. Najafzadeh M, Gagne JJ, Choudhry NK, Polinski JM, Avorn J, Schneeweiss SS. Patients' preferences in anticoagulant therapy: discrete choice experiment. Circ Cardiovasc Qual Outcomes. 2014 Nov; 7(6):912-9.
    View in: PubMed
    Score: 0.166
  44. Sarpatwari A, Kesselheim AS, Malin BA, Gagne JJ, Schneeweiss S. Ensuring patient privacy in data sharing for postapproval research. N Engl J Med. 2014 Oct 23; 371(17):1644-9.
    View in: PubMed
    Score: 0.165
  45. Wang SV, Schneeweiss S, Maclure M, Gagne JJ. "First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs. Am J Epidemiol. 2014 Sep 15; 180(6):636-44.
    View in: PubMed
    Score: 0.162
  46. Wang SV, Gagne JJ, Glynn RJ, Schneeweiss S. Case-crossover studies of therapeutics: design approaches to addressing time-varying prognosis in elderly populations. Epidemiology. 2013 May; 24(3):375-8.
    View in: PubMed
    Score: 0.149
  47. Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012 Jul 01; 5(4):480-6.
    View in: PubMed
    Score: 0.141
  48. Glynn RJ, Gagne JJ, Schneeweiss S. Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf. 2012 May; 21 Suppl 2:138-47.
    View in: PubMed
    Score: 0.139
  49. Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther. 2011 Dec; 90(6):777-90.
    View in: PubMed
    Score: 0.134
  50. Goldberg NH, Schneeweiss S, Kowal MK, Gagne JJ. Availability of comparative efficacy data at the time of drug approval in the United States. JAMA. 2011 May 04; 305(17):1786-9.
    View in: PubMed
    Score: 0.130
  51. Fireman B, Gruber S, Zhang Z, Wellman R, Nelson JC, Franklin J, Maro J, Murray CR, Toh S, Gagne J, Schneeweiss S, Amsden L, Wyss R. Consequences of Depletion of Susceptibles for Hazard Ratio Estimators Based on Propensity Scores. Epidemiology. 2020 Nov; 31(6):806-814.
    View in: PubMed
    Score: 0.063
  52. Wyss R, Gagne JJ, Zhao Y, Zhou EH, Major JM, Wang SV, Desai RJ, Franklin JM, Schneeweiss S, Toh S, Johnson M, Fireman B. Use of Time-Dependent Propensity Scores to Adjust Hazard Ratio Estimates in Cohort Studies with Differential Depletion of Susceptibles. Epidemiology. 2020 01; 31(1):82-89.
    View in: PubMed
    Score: 0.059
  53. Gopalakrishnan C, Gagne JJ, Sarpatwari A, Dejene SZ, Dutcher SK, Levin R, Franklin JM, Schneeweiss S, Desai RJ. Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use. Clin Pharmacol Ther. 2019 06; 105(6):1513-1521.
    View in: PubMed
    Score: 0.056
  54. Wang SV, Maro JC, Baro E, Izem R, Dashevsky I, Rogers JR, Nguyen M, Gagne JJ, Patorno E, Huybrechts KF, Major JM, Zhou E, Reidy M, Cosgrove A, Schneeweiss S, Kulldorff M. Data Mining for Adverse Drug Events With a Propensity Score-matched Tree-based Scan Statistic. Epidemiology. 2018 11; 29(6):895-903.
    View in: PubMed
    Score: 0.055
  55. Spoendlin J, Gagne JJ, Lewey JJ, Patorno E, Schneeweiss S, Desai RJ. Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome. Pharmacoepidemiol Drug Saf. 2018 Dec; 27(12):1361-1370.
    View in: PubMed
    Score: 0.055
  56. Wang SV, Schneeweiss S, Gagne JJ, Evers T, Gerlinger C, Desai R, Najafzadeh M. Using Real-World Data to Extrapolate Evidence From Randomized Controlled Trials. Clin Pharmacol Ther. 2019 05; 105(5):1156-1163.
    View in: PubMed
    Score: 0.054
  57. Wang SV, Kulldorff M, Glynn RJ, Gagne JJ, Pottegård A, Rothman KJ, Schneeweiss S, Walker AM. Reuse of data sources to evaluate drug safety signals: When is it appropriate? Pharmacoepidemiol Drug Saf. 2018 06; 27(6):567-569.
    View in: PubMed
    Score: 0.053
  58. Hallas J, Wang SV, Gagne JJ, Schneeweiss S, Pratt N, Pottegård A. Hypothesis-free screening of large administrative databases for unsuspected drug-outcome associations. Eur J Epidemiol. 2018 Jun; 33(6):545-555.
    View in: PubMed
    Score: 0.052
  59. Martin D, Gagne JJ, Gruber S, Izem R, Nelson JC, Nguyen MD, Ouellet-Hellstrom R, Schneeweiss S, Toh S, Walker AM. Sequential surveillance for drug safety in a regulatory environment. Pharmacoepidemiol Drug Saf. 2018 07; 27(7):707-712.
    View in: PubMed
    Score: 0.052
  60. Krumme AA, Glynn RJ, Schneeweiss S, Gagne JJ, Dougherty JS, Brill G, Choudhry NK. Medication Synchronization Programs Improve Adherence To Cardiovascular Medications And Health Care Use. Health Aff (Millwood). 2018 01; 37(1):125-133.
    View in: PubMed
    Score: 0.051
  61. Wang SV, Schneeweiss S, Berger ML, Brown J, de Vries F, Douglas I, Gagne JJ, Gini R, Klungel O, Mullins CD, Nguyen MD, Rassen JA, Smeeth L, Sturkenboom M. Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Value Health. 2017 09; 20(8):1009-1022.
    View in: PubMed
    Score: 0.050
  62. Wang SV, Schneeweiss S, Berger ML, Brown J, de Vries F, Douglas I, Gagne JJ, Gini R, Klungel O, Mullins CD, Nguyen MD, Rassen JA, Smeeth L, Sturkenboom M. Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. Pharmacoepidemiol Drug Saf. 2017 09; 26(9):1018-1032.
    View in: PubMed
    Score: 0.050
  63. Bateman BT, Bykov K, Choudhry NK, Schneeweiss S, Gagne JJ, Polinski JM, Franklin JM, Doherty M, Fischer MA, Rassen JA. Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. BMJ. 2013 Sep 19; 347:f5416.
    View in: PubMed
    Score: 0.038
  64. Bateman BT, Rassen JA, Schneeweiss S, Bykov K, Franklin JM, Gagne JJ, Polinski JM, Liu J, Kulik A, Fischer MA, Choudhry NK. Adjuvant vancomycin for antibiotic prophylaxis and risk of Clostridium difficile infection after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg. 2013 Aug; 146(2):472-8.
    View in: PubMed
    Score: 0.037
  65. Kulik A, Rassen JA, Myers J, Schneeweiss S, Gagne J, Polinski JM, Liu J, Fischer MA, Choudhry NK. Comparative effectiveness of preventative therapy for venous thromboembolism after coronary artery bypass graft surgery. Circ Cardiovasc Interv. 2012 Aug 01; 5(4):590-6.
    View in: PubMed
    Score: 0.035
  66. Wahl PM, Gagne JJ, Wasser TE, Eisenberg DF, Rodgers JK, Daniel GW, Wilson M, Schneeweiss S, Rassen JA, Patrick AR, Avorn J, Bohn RL. Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples. Drug Saf. 2012 May 01; 35(5):407-16.
    View in: PubMed
    Score: 0.035
  67. Myers JA, Rassen JA, Gagne JJ, Huybrechts KF, Schneeweiss S, Rothman KJ, Joffe MM, Glynn RJ. Effects of adjusting for instrumental variables on bias and precision of effect estimates. Am J Epidemiol. 2011 Dec 01; 174(11):1213-22.
    View in: PubMed
    Score: 0.034
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.